Croton sylvaticus is a medicinal plant widely employed in the management of inflammatory conditions, infections and oxidative stress related diseases such as insomnia, abdominal and internal inflammations. The activities demonstrated by the plant extracts support that its constituents possess the ability to reduce oxidative damage to body cells.Repeated column fractionation of the ethyl acetate fraction of a 20% aqueous methanol leaf extract using acetylcholinesterase (AChE) activity directed on Sephadex LH-20 afforded three compounds identified by mass spectrometry, and 1D and 2D NMR spectroscopy as: 2'-(3'',4''dihydroxyphenyl)-ethyl-4-hydroxybenzoate (1), 3, 3', 4', 5, 7-pentahydroxyflavone (quercetin) (2), and 3, 4', 5, 7-tetrahydroxyflavone (kaempferol) (3). These compounds are reported from the leaf extracts of C. sylvaticus for the first time and compound 1 is a new natural product. The microplate technique was used to determine the inhibitory effects of the plant extracts (crude and solvent fractions) and isolated compounds against AChE. The IC 50 values of the compounds ranged from 60.7 to 415.0 µg/mL, with compound 2 having the best inhibitory activity; the IC 50 values of the plant crude extract and solvent fractions ranged from 235.0 to 4695.0 µg/mL. The ethyl acetate fraction had the best inhibitory activity (IC 50 =235.0 µg/mL). The three compounds showed no mutagenic effects against Salmonella typhimurium tester strains TA98 and TA100. The activity demonstrated by these compounds suggests that they could be effective in the management of neurodegenerative disorders.
Croton sylvaticus Hochst. is commonly known as the forest feverberry. It belongs to the family Euphorbiaceae and grows up to 20 m high. The wood shavings are used as a remedy for elephantiasis. The seeds and its oil are used as purgatives [1] .The leaves mixed with those of other Croton species are used for the treatment of insomnia [2] . It is widely used to treat abdominal disorders [3] . The stem bark and root are used in the following conditions: abdominal and internal inflammations, uterine disorders, as a purgative, for pleurisy, indigestion, tuberculosis and rheumatism [4] . Acetone leaf extracts of C. sylvaticus demonstrated good antifungal activity against Cryptococcus neoformans [5] , while dichloromethane, methanol and aqueous extracts showed 5-lipoxygenase inhibitory and antioxidant activities [6, 7] . Phytochemical investigation of the leaf extracts yielded a novel lactonized clerodanefurano diterpenoid, along with clerodane diterpenoids [8] .
The use of Croton species in management of inflammatory and oxidative stress related conditions [9, 10] support that their constituents could possess the ability to reduce oxidative damage to cells. The purpose of this study was to investigate the constituents of C. sylvaticus for potential acetylcholinesterase inhibitory activity which could be useful in ameliorating neurodegenerative disorders. Safety of the isolated compounds from the leaf extracts was investigated by determining their mutagenicity.
Repeated column fractionation of the ethyl acetate fraction of a 20% aqueous methanol leaf extract using AChE activity directed on Sephadex LH-20 afforded three compounds identified by mass spectrometry, and 1D and 2D NMR spectroscopy.
Compound 1 was obtained as cream powder. Its mass spectrum (TOF-MS-ES) showed the exact molecular ion peak as the base peak at m/z = 273.0761, the [M-H] -, consistent with the molecular formula C 15 H 14 O 5. Calculated molecular mass for the compound was 273.0763. The 1 H NMR spectrum of 1 (Table 1) showed signals between δ 7.91-6.91 for two separate doublets (ortho coupled related protons, 2H each) for a 1, 4-disubstituted phenyl ring representing an A 2 B 2 ring system. Another two doublets appeared at δ 6.71 (1H, d, J = 8.0 Hz, H-5'') and 6.70 (1H, d, J = 2.0 Hz, H-2'') along with a doublet of doublet at δ 6.53 (1H, d, J= 2.0, 8.0 Hz, H-6'') representing a 1,3,4-trisubstituted phenyl ring indicating an ABX group. Also, the signals for the presence of an ethylene group appeared at δ 3.66 (2H, H-1') and δ 2.64 (2H, H-2' ( Table 1 ). 13 C NMR and DEPT spectra of this compound revealed the presence of 13 carbons. These were classified as two CH 2 , five assigned to a p-hydroxybenzoate group and six to an ABX ring unit. The positions of attachment of the ethylene, trisubstituted phenyl unit and the benzoate unit were established by HMBC correlations, as depicted in Figure 1 .
Compound 1 was determined to be 2'-(3'', 4''-dihydroxyphenyl)ethyl-4-hydroxy benzoate ( Figure 2 ). To the best of our knowledge this is the first report of this compound as natural product. Closely related phenyl propanoid analogues: namely 3'-(4''hydroxyphenyl)propyl benzoate and 3'-(4'' hydroxy-3'',5''dimethoxyphenyl)-propyl benzoate were recently reported from Croton laevigatus and C. hutchinsonianus [11, 12] .
The spectral data (MS, 1 H and 13 C NMR) of compounds 2 and 3 closely matched those of 3, 3', 4', 5, 7-pentahydroxyflavone (quercetin) and 3, 4', 5, 7-tetrahydroxyflavone (kaempferol), respectively [13] , and these identities were assigned to 2 and 3, respectively. Table 2 . Figure 3 represents the dose dependent increase in the inhibition of AChE by the crude extract and the four solvent fractions, while Table 2 lists the IC 50 values.
The n-butanol fraction exhibited the highest percentage inhibitory activity at the highest concentration of 5000 µg/mL, while the DCM fraction had the least. At the same concentration, however, all the fractions exhibited a better inhibitory activity compared with the crude extract.
Ranking the fractions according to their IC 50 values resulted in this order of potency; ethyl acetate > n-hexane > n-butanol > DCM.
Considering the potency of the fractions, as reflected by the IC 50 values, further investigation of the ethyl acetate fraction afforded three compounds, as discussed above. The three compounds are reported from the leaf extracts of C. sylvaticus for the first time, while compound 1 is a new natural product. The compounds were subjected to the same assay and Figure 4 depicts the dose dependent increase in the percentage inhibitory activities, while Table 2 lists the IC 50 values of the compounds. The IC 50 values ranged from 60.7 µg/mL (compound 2) to 415.0 µg/mL (compound 1) and the order of potency was compound 2 > compound 3 > compound 1. All three compounds are phenolic in nature and are bound to exhibit some pharmacological and biological activities. This was confirmed with the results obtained for the inhibitory activity of these compounds towards AChE (Figures 3, 4 and Table 2 ). Compounds with AChE inhibitory effects may be helpful in the treatment of a number of neurodegenerative disorders such as Alzheimer's' disease, Parkinsonism, myasthenia gravis and senile dementia [14] . The identification of new inhibitors of AChE with fewer side effects is urgently required [15] . 131.2 ± 9.9 4-NQO; 4-nitroquinoline-oxide was used as a positive control at 2 µg/mL (for TA98, revertant colonies were 208.0 ± 0.6; TA100, revertant colonies were 992.3 ± 9.3). 10% DMSO (in water) was used as a negative control (for TA98, revertant colonies were 22.0 ± 1.6; TA100, revertant colonies were 174.5 ± 4.1).
A test compound is only classified as a 'mutagen' if the result satisfies two criteria (1) a dose dependent increase in the number of revertant colonies is observed and (2) the number of revertant colonies is equal to or greater than two times that of the negative control [16, 17] . In this case, the average His + reversion induced by the test compounds for all the tester strains, at all the concentrations, did not satisfy the criteria for mutagenicity. There were no notable dose dependent increases in the number of revertants and the numbers were not equal to or greater than two times that of the negative control.These compounds, therefore, do not have the capacity to cause mutation. However, confirmatory tests using other techniques, as well as toxicity studies, are urgently required.
Experimental
General: All TLC analyses were performed at room temperature using pre-coated plates (Merck, silica gel 60 F 254 0.2 mm). Detection of compounds was by ultraviolet light (254 and 366 nm). Open CC was carried out using Sephadex LH-20. 1 H NMR (400 MHz) and 13 C NMR (100 MHz) spectra were recorded on a Brucker spectrometer. Chemical shifts are expressed in parts per million (ppm). Mass spectra (TOF MS ES) were recorded using a Thermofinnigan Trace GC coupled to a Polaris Q Mass Spectrometer.
Plant material:
The leaves of C. sylvaticus were collected in March 2012 in the medicinal garden, School of Life Sciences, University of KwaZulu-Natal. The plant was identified by Mrs A. Young (Horticulturist, UKZN). A voucher specimen (Aderogba MA 01) was deposited at the Bews Herbarium (NU) of the University of KwaZulu-Natal. The collected plant material was oven dried at 45ºC for 3 days and ground to powder.
Extraction:
The powdered leaves of C. sylvaticus (1.0 kg) were extracted with 8 L of 20% aqueous methanol at room temperature for 24 h and filtered. The crude extract was concentrated in vacuo at 40ºC to about ¼ of the original volume. This afforded crude extract (900 mL) of the plant material.
Solvent partitioning of the crude extract:
Concentrated crude extract (900 mL) was in turn sequentially extracted with n-hexane (3 x 800 mL), dichloromethane (3 x 800 mL), ethyl acetate (3 x 1 L) and finally n-butanol (2 x 500 mL). The solvent fractions were concentrated to dryness in vacuo to afford 4 solvent fractions: nhexane (Hex), (4.8 g), dichloromethane (DCM), (5.0 g), ethyl acetate (EtOAc), (2.1 g) and n-butanol (15.5 g). The most active fraction (EtOAc) was selected for column fractionation in order to isolate, characterize and evaluate the AChE activity of its constituents.
Isolation of compounds from C. sylvaticus extracts:
The EtOAc fraction (1.5 g) was subjected to AChE activity directed fractionation using a Sephadex LH-20 column and 95% DCM/MeOH mixture as eluent. This was followed by an increasing gradient of methanol up to 30%. The fractions collected were analysed by TLC using DCM/MeOH (9:1) as solvent system. This afforded 4 fractions (A 1 -A 4 ). Fraction A 1 (170 mg) was further fractionated on Sephadex LH-20 using EtOAc/MeOH (9.5:0.5) as eluent. The fractions collected were analyzed by TLC using DCM/MeOH (9:1) as solvent system. This gave 3 fractions B 1 -B 3 . Fraction B 3 (60 mg) was subsequently purified on Sephadex LH-20 using DCM/MeOH (9:1) as eluent. Analysis of the fractions collected by TLC yielded compound 1 (4 mg). Fraction A 2 (65 mg) contained one major compound that was purified on Sephadex LH 20 using EtOAc/MeOH (9:1); this afforded compound 3 (9 mg). Fraction A 4 also contained one major compound that was purified on Sephadex LH-20 using EtOAc /MeOH (9:1). Analysis of the fractions collected from the TLC plates using DCM/MeOH (8.5:1.5) yielded compound 2 (7 mg). 
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